Blonanserin

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

First Episode Schizophrenia

Conditions

First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin

Trial Timeline

Jan 22, 2019 โ†’ Nov 22, 2022

About Blonanserin

Blonanserin is a approved stage product being developed by Sumitomo Pharma for First Episode Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03784222. Target conditions include First Episode Schizophrenia, Social Function, Cognition Function.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03784222ApprovedTerminated